BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26604135)

  • 1. Dasatinib as a treatment for Duchenne muscular dystrophy.
    Lipscomb L; Piggott RW; Emmerson T; Winder SJ
    Hum Mol Genet; 2016 Jan; 25(2):266-74. PubMed ID: 26604135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies.
    Sanarica F; Mantuano P; Conte E; Cozzoli A; Capogrosso RF; Giustino A; Cutrignelli A; Cappellari O; Rolland JF; De Bellis M; Denora N; Camerino GM; De Luca A
    Pharmacol Res; 2019 Jul; 145():104260. PubMed ID: 31059789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse.
    Miller G; Moore CJ; Terry R; La Riviere T; Mitchell A; Piggott R; Dear TN; Wells DJ; Winder SJ
    Hum Mol Genet; 2012 Oct; 21(20):4508-20. PubMed ID: 22810924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Dystroglycan Restoration and Pathology Progression in the Dystrophic
    Mantuano P; Boccanegra B; Conte E; De Bellis M; Cirmi S; Sanarica F; Cappellari O; Arduino I; Cutrignelli A; Lopedota AA; Mele A; Denora N; De Luca A
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment.
    Li M; Andersson-Lendahl M; Sejersen T; Arner A
    FASEB J; 2014 Apr; 28(4):1593-9. PubMed ID: 24371125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
    Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug screening in a zebrafish model of Duchenne muscular dystrophy.
    Kawahara G; Karpf JA; Myers JA; Alexander MS; Guyon JR; Kunkel LM
    Proc Natl Acad Sci U S A; 2011 Mar; 108(13):5331-6. PubMed ID: 21402949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.
    Waugh TA; Horstick E; Hur J; Jackson SW; Davidson AE; Li X; Dowling JJ
    Hum Mol Genet; 2014 Sep; 23(17):4651-62. PubMed ID: 24760771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs.
    Araujo KP; Bonuccelli G; Duarte CN; Gaiad TP; Moreira DF; Feder D; Belizario JE; Miglino MA; Lisanti MP; Ambrosio CE
    PLoS One; 2013; 8(4):e61367. PubMed ID: 23579193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alisporivir rescues defective mitochondrial respiration in Duchenne muscular dystrophy.
    Schiavone M; Zulian A; Menazza S; Petronilli V; Argenton F; Merlini L; Sabatelli P; Bernardi P
    Pharmacol Res; 2017 Nov; 125(Pt B):122-131. PubMed ID: 28899790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice.
    Bizario JC; Cerri DG; Rodrigues LC; Oliveira GL; Nomizo A; de Araujo DD; Fukuhara PS; Ribeiro JC; de Castro FA; Costa MC
    J Neuroimmunol; 2009 Jul; 212(1-2):93-101. PubMed ID: 19508953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy.
    Farr GH; Morris M; Gomez A; Pham T; Kilroy E; Parker EU; Said S; Henry C; Maves L
    Skelet Muscle; 2020 Oct; 10(1):29. PubMed ID: 33059738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.
    Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM
    Skelet Muscle; 2016; 6():20. PubMed ID: 27257474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid Steroid and Alendronate Treatment Alleviates Dystrophic Phenotype with Enhanced Functional Glycosylation of α-Dystroglycan in Mouse Model of Limb-Girdle Muscular Dystrophy with FKRPP448L Mutation.
    Wu B; Shah SN; Lu P; Richardson SM; Bollinger LE; Blaeser A; Madden KL; Sun Y; Luckie TM; Cox MD; Sparks S; Harper AD; Lu QL
    Am J Pathol; 2016 Jun; 186(6):1635-48. PubMed ID: 27109613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment.
    Colussi C; Mozzetta C; Gurtner A; Illi B; Rosati J; Straino S; Ragone G; Pescatori M; Zaccagnini G; Antonini A; Minetti G; Martelli F; Piaggio G; Gallinari P; Steinkuhler C; Clementi E; Dell'Aversana C; Altucci L; Mai A; Capogrossi MC; Puri PL; Gaetano C
    Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19183-7. PubMed ID: 19047631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research.
    Muntoni F; Fisher I; Morgan JE; Abraham D
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S162-5. PubMed ID: 12206811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic overexpression of dystroglycan does not inhibit muscular dystrophy in mdx mice.
    Hoyte K; Jayasinha V; Xia B; Martin PT
    Am J Pathol; 2004 Feb; 164(2):711-8. PubMed ID: 14742274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolysis of beta-dystroglycan in muscular diseases.
    Matsumura K; Zhong D; Saito F; Arai K; Adachi K; Kawai H; Higuchi I; Nishino I; Shimizu T
    Neuromuscul Disord; 2005 May; 15(5):336-41. PubMed ID: 15833425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.